PRJ1-3024

DRUG3 trials

Sponsors

Zhuhai Yufan Biotechnologies Co., Ltd

Conditions

Advanced Solid MalignanciesAdvanced Solid TumorMelanoma

Phase 1

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Active, not recruitingNCT05159700

Zhuhai Yufan Biotechnologies Co., LtdAdvanced Solid Malignancies, Advanced Solid Tumor

Start: 2022-03-31End: 2026-06-29Updated: 2025-12-15

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

RecruitingNCT05315167

Zhuhai Yufan Biotechnologies Co., LtdAdvanced Solid Malignancies, Advanced Solid Tumor

Start: 2022-05-30End: 2027-11-15Target: 267Updated: 2024-12-17

A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

RecruitingNCT06727630

Zhuhai Yufan Biotechnologies Co., LtdMelanoma

Start: 2024-03-14End: 2025-10-30Target: 40Updated: 2024-12-11

Related Papers

A phase I/II study to evaluate the safety, pharmacokinetics, and efficacy of PRJ1-3024 in patients with advanced solid tumors.

Journal of Clinical Oncology2024-06-011 citations

1073 A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1–3024in subjects with advanced solid tumors

Regular and Young Investigator Award Abstracts2023-10-31